Pautier P
Service d'Oncologie Moléculaire, Pavillon de Recherche n. 1, Institut Gustave Roussy, Villejuif, France.
Pathol Biol (Paris). 1992 Dec;40(9 Pt 2):956-9.
Sessions about lung cancer of the 28th annual meeting of ASCO approached especially non small cell lung cancer (NSCLC). Undoubtedly the outstanding facts for this pathology was first the acknowledgment of the importance of a correct staging system, in particular in stage IIIA for which resection is a prognostic factor different for tumors T3N0, T3N1 as for N2. Two important topics have been discussed on therapy: stage IIIA treatment, in particular neoadjuvant therapy before surgery, and new drugs like Navelbine, taxol, and campthotecine which suggest the possibility of improvements for chemotherapy of NSCLC in the next few years. For small cell lung cancer (SCLC), different trials were designed to improve dose intensity with growth factors, fractionation of therapy, autologous bone marrow transplantation.
美国临床肿瘤学会第28届年会中关于肺癌的会议特别聚焦于非小细胞肺癌（NSCLC）。毫无疑问，对于这种病理类型而言，突出的事实首先是认识到正确分期系统的重要性，特别是在IIIA期，对于T3N0、T3N1和N2肿瘤，切除是一个不同的预后因素。关于治疗讨论了两个重要话题：IIIA期治疗，特别是术前新辅助治疗，以及诸如诺维本、紫杉醇和喜树碱等新药，这表明未来几年非小细胞肺癌化疗有可能得到改善。对于小细胞肺癌（SCLC），设计了不同的试验来提高剂量强度，包括使用生长因子、分割治疗、自体骨髓移植。
